A Phase 3 interventional study of Reminder message and patient navigation in Neurodevelopmental Disorders, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.. Recruiting at 1 site in United States. Open to participants aged 1 Month to 24 Years. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Phase 3, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Neurodevelopmental Disorders with a site in United States — 37 open to participants now, 53 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.
Among the 100 studies in Neurodevelopmental Disorders with a site in United States, this one has the largest planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 11 of the 52 other live ones, and was the 87th registered.
355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.
Browse Neurodevelopmental Disorders studies →37 of the 100 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 6 mo+
Life University · Sites in United States
Ages 8+
UCB Biopharma SRL · Sites in United States, France, Spain
Ages up to 17
Healing Hope International · Sites in United States
Ages 4–12
GRIN Therapeutics, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 1 mo–18 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: 1 Month to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 1996; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 86 across 218 interventional studies indexed under Neurodevelopmental Disorders.
Median enrollment 100 across the 60 interventional studies, 158 across the 40 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 100 have an industry lead sponsor. The 10 most frequent:
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. is the lead sponsor of 76 studies on the registry; 19 are open to participants now.
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
19 of the studies in Neurodevelopmental Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06915480Phase 3Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Reducing Missed Appointments | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT03770832Shirley Ryan AbilityLabWearable Sensors and Video Recordings to Monitor Motor Development | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 100 studies in Neurodevelopmental Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are four goals of this project: (1) To examine the impact of different appointment reminder messages on appointment attendance; (2) to determine the added benefit of a patient navigator reaching out in advance of appointments to families at elevated risk of missing their appointment, and determine the most common barriers families face in appointment attendance; (3) to evaluate which patients are at highest risk of missing their appointment, and to determine the effectiveness of the intervention trial across different patient risk levels; and (4) to examine if the missing appointment interventions increase the socioeconomic diversity patients.
Aim 1: To test messaging strategies aimed at reducing missed appointments, via a randomized trial, across two different Kennedy Krieger outpatient clinics. Using the reminder system timeline and contact strategy already in effect in these two centers, the investigators will trial alternative language in the reminders (i.e., enhanced message #1 and enhanced message #2) against the current standard of care language. Hypothesis 1: Enhanced messaging will be superior to the standard of care in terms of reducing missed appointments. The investigators do not make a priori hypotheses regarding which enhanced messaging strategy will be optimal, given the exploratory nature.
Aim 2: To determine the added benefit of receiving patient navigation services for families at elevated risk of missing their appointment, and to understand the barriers to child neurodevelopmental evaluation appointments for the purposes of informing future interventions. Throughout the intervention trial, the patient navigator will continuously gather qualitative information on the barriers to appointment attendance faced by families identified to be at elevated risk of missing their evaluation appointment. Understanding these barriers will be critical to the development of future intervention efforts. Hypothesis 2a: Patient navigation services will be superior to enhanced or standard messaging alone in reducing missed appointments. Hypothesis 2b: Most families contacted by the patient navigator will face more than one barrier to attendance, and most barriers will fall into thematic categories that can be used to develop targeted interventions.
Aim 3: To examine the factors related to missed appointments. While the study team has previously identified families that are high-risk for missing their child's appointment, how those family and child-related factors replicate in a novel clinic is unknown. Hypothesis 3: The missing appointment factors will generally reproduce in an independent clinic, Center for Autism (n\~3600 yearly diagnostic evaluation appointments), and generally reproduce in the updated data within Center for Neuropsychological and Psychological Assessment (n\~6,200 yearly diagnostic evaluation appointments). This will allow the investigators to determine if the intervention is effective particularly for families at elevated risk of missing their appointment (Aim 4).
Aim 4: To examine if the missing appointment interventions increase the socioeconomic diversity of Kennedy Krieger patients. Previous research shows families from less advantaged socioeconomic backgrounds are more likely to miss their appointments. The goal of the intervention is to increase equity among Kennedy Krieger patients, rather than sacrificing equity at the expense of higher show rates (e.g., using punitive procedures). Hypothesis 4: More families at elevated risk of missing their appointments will attend their appointments when receiving the enhanced messages compared to standard messages, and further supported via patient navigation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
This arm represents the standard operating procedures. It includes basic appointment information and no personal assistance with appointment navigation.
Behavioral: Reminder message and patient navigation
This arm represents the standard pre-appointment reminder message. This arm will include personal assistance with appointment navigation.
Behavioral: Reminder message and patient navigation
This arm represents a novel pre-appointment reminder message based on existing scientific literature. This arm will not include personal assistance with appointment navigation.
Behavioral: Reminder message and patient navigation
This arm represents a novel pre-appointment reminder message based on existing scientific literature. This arm will include personal assistance with appointment navigation.
Behavioral: Reminder message and patient navigation
This arm represents a second novel pre-appointment reminder message based on existing scientific literature. This arm will not include personal assistance with appointment navigation.
Behavioral: Reminder message and patient navigation
This arm represents a second novel pre-appointment reminder message based on existing scientific literature. This arm will include personal assistance with appointment navigation.
Behavioral: Reminder message and patient navigation
This study will evaluate the combination of pre-appointment messages and patient navigation services.
Patient appointment no-show
Proportion of appointments that are neither kept nor cancelled
Time frame: 6 months
Patient appointment cancel
Proportion of appointments that are cancelled (\>48 hours of appointment date)
Time frame: 6 months
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.